Considering recent data on the immunosuppressive role of TICs/CSCs in several cancer entities [69] as well as the regulation of immunosuppressive factors by GLI [70,71,72,73] combination therapy with CSNK1D and immune checkpoint inhibitors is an attractive therapeutic strategy to be evaluated in follow-up pre-clinical studies. This evidence concerns the gene GLI1 and cancer.